At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 957 enrolled
Drug / intervention
MT10109L Dose 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines
In Brief
A Phase 3 clinical trial evaluating MT10109L Dose 1, MT10109L Dose 2, and 1 other intervention for Glabellar Lines and Lateral Canthal Lines. Completed, enrolled 957 participants across 38 sites in 6 countries.
Detailed Summary
To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Lines, Lateral Canthal Lines
CountriesBelgium, Canada, Germany, Russia, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedNov 2019
Primary CompletionFeb 2023
TodayJul 2026
First PostedNov 8, 2019
Enrollment StartOct 23, 2019
Primary CompletionFeb 16, 2023
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.6 years ago
Interventions
MT10109L Dose 1drug
MT10109L Dose 1 will be injected into the GL area
MT10109L Dose 2drug
MT10109L Dose 2 will be injected into the LCL area
MT10109L Dose 1 + Dose 2drug
MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area